SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I weekly-dosing clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), including multiple complete and partial remissions in patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma (ALCL). The data were presented at the American Society of Hematology (ASH) 51st Annual Meeting being held in New Orleans, Louisiana.
